|
Herpesvirus varicellae
|
Attenuated live virus
|
Recipients of bone narrow and organ transplants and persons under age 25 with leukemias and lymphomas
|
558
|
337
|
320
|
237
|
372
|
231
|
219
|
162
|
|
|
|
Normal susceptibles, routine for children (booster for adults)
|
1391
|
1112
|
445
|
167
|
960
|
746
|
298
|
112
|
|
Influenza viruses A & B
|
Subunit vaccine (purified hemagglutinin/ neuramindase proteins)
|
High-risk population as currently defined (see Appendix K)
|
10644
|
9048
|
814
|
521
|
28225
|
23991
|
2159
|
1381
|
|
|
Attenuated live virus
|
High-risk population as currently defined
|
10644
|
9048
|
1357
|
504
|
28225
|
23991
|
3599
|
1336
|
|
Neisseria gonorrhoeae
|
A small number of promising options need investigation to determine best approach
|
Adolescents and adults age 15 and over
|
527
|
444
|
44
|
8
|
13811
(347)
|
11738
(294)
|
1174
(29.4)
|
201
(5)
|
|
Parainfluenza viruses
|
Trivalent, subunit vaccine (must contain fusion protein)
|
Infants
|
660
|
561
|
297
|
132
|
584
|
496
|
263
|
117
|
|
Respiratory Syncytial virus
|
Glycoprotein produced by recombinant DNA technology
|
Infants
|
3827
|
3062
|
980
|
458
|
3775
|
3020
|
966
|
452
|
|
|
Attenuated live virus
|
Infants
|
3827
|
3062
|
1623
|
759
|
3775
|
3020
|
1601
|
749
|
|
Rotavirus
|
Attenuated live bovine virus
|
Infants
|
281
|
253
|
68
|
41
|
227
|
204
|
55
|
33
|
|
|
Attenuated live human or reassortment virus
|
Infants
|
281
|
253
|
68
|
38
|
227
|
204
|
55
|
30
|
|
Streptococcus group B
|
Conjugated polysaccharide
|
Pregnant women for fetuses and neonates
|
3570
|
2856
|
314
|
125
|
3528
|
2823
|
311
|
124
|
|
aSee text and appendixes for explanation and derivation.
bAdjusted for vaccine efficacy; see text for explanation where efficacy varies with conditions.
cAdjusted for anticipated utilization.
dAdjusted for probability of success and time at which steady state of benefits would be achieved.
|
